At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets. Others are building towards a future transformation of the drug development process … for Ventus, that future is already here. Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged or for which existing chemical matter leaves significant room for improvement. We are differentiated by our unique methods for modelling the properties of protein and water in motion. Optimal execution of these methods requires embedding our ReSOLVE platform with our world-class structural biology and chemistry teams. As our pipeline demonstrates, the ReSOLVE platform can find previously unknown pockets, better characterize known pockets, and solve the limitations of virtual screening, accelerating medicinal chemistry and structure-activity relationship (SAR) optimization. We are advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer, and also generating a library of chemical matter for elusive targets for future pipeline needs and business development. Our team includes experienced biopharmaceutical executives, scientists who have delivered multiple approved medicines, and luminary academics spanning the fields of structural biology, immunology, and computational chemistry.